Table 2 Demographic, clinical and laboratory characteristics of individuals with HIV in West and Central Africa (2016–2020)
From: Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa
|  | Côte d’Ivoire | Gabon | Togo | Burkina Faso | Total |
|---|---|---|---|---|---|
(n = 1453) | (n = 951) | (n = 1112) | (n = 500) | (n = 4016) | |
Sex | |||||
 Male | 483 (33.2) | 303 (31.9) | 329 (29.6) | 96 (19.2) | 1211 (30.2) |
 Female | 970 (66.8) | 648 (68.1) | 783 (70.4) | 404 (80.8) | 2805 (69.8) |
Age (years), Median [IQR] | 46 [40–53] | 44 [36–52] | 44 [37–51] | 44 [38–51] | 45 [38–52] |
Age (years) | |||||
  < 20 | 3 (0.2) | 21 (2.2) | 12 (1.1) | 1 (0.2) | 37 (0.9) |
 20–29 | 55 (3.8) | 88 (9.3) | 76 (6.8) | 19 (3.8) | 238 (5.9) |
 30–39 | 283 (19.5) | 238 (25.0) | 267 (24.0) | 142 (28.4) | 930 (23.2) |
 40–49 | 584 (40.2) | 322 (33.9) | 426 (38.3) | 196 (39.2) | 1528 (38.0) |
 50–59 | 399 (27.5) | 198 (20.8) | 256 (23.0) | 118 (23.6) | 971 (24.2) |
  ≥ 60 | 129 (8.9) | 84 (8.8) | 75 (6.7) | 24 (4.8) | 312 (7.8) |
Education level | |||||
 None | 499 (34.3) | 186 (19.6) | 199 (17.9) | 202 (40.4) | 1086 (27.0) |
 Primary | 301 (20.7) | 148 (15.6) | 390 (35.1) | 209 (41.8) | 1048 (26.1) |
 Secondary | 435 (29.9) | 448 (47.1) | 454 (40.8) | 84 (16.8) | 1421 (35.4) |
 University | 218 (15.0) | 169 (17.8) | 69 (6.2) | 5 (1.0) | 461 (11.5) |
Time since HIV diagnosis (years) | |||||
  < 1 | 78 (5.4) | 135 (14.2) | 126 (11.3) | 20 (4.0) | 359 (8.9) |
 [1–3] | 132 (9.1) | 170 (17.9) | 160 (14.4) | 43 (8.6) | 505 (12.6) |
 [3–5] | 155 (10.7) | 147 (15.5) | 144 (12.9) | 52 (10.4) | 498 (12.4) |
  ≥ 5 | 1065 (73.3) | 389 (40.9) | 666 (59.9) | 384 (76.8) | 2504 (62.4) |
 Missing | 23 (1.6) | 110 (11.6) | 16 (1.4) | 1 (0.2) | 150 (3.7) |
CD4 cell count, Median [IQR] | 230 [127–367] | 237 [138–440] | 169 [84–297] | 227 [110–333] | 210 [106–340] |
Baseline CD4 cell count (cells/mm3) | |||||
  < 200 | 563 (38.7) | 78 (8.2) | 549 (49.4) | 201 (40.2) | 1391 (34.6) |
 [200–350] | 407 (28.0) | 56 (5.9) | 243 (21.9) | 148 (29.6) | 854 (21.3) |
 [350–500] | 177 (12.2) | 25 (2.6) | 111 (10.0) | 58 (11.6) | 371 (9.2) |
  ≥ 500 | 188 (12.9) | 40 (4.2) | 52 (4.7) | 47 (9.4) | 327 (8.1) |
 Missing | 118 (8.1) | 752 (79.1) | 157 (14.1) | 46 (9.2) | 1073 (26.7) |
HIV status | |||||
 HIV-1 | 1370 (94.3) | 734 (77.2) | 1078 (96.9) | 469 (93.8) | 3651 (90.9) |
 HIV-2 | 37 (2.5) | 4 (0.4) | 7 (0.6) | 17 (3.4) | 65 (1.6) |
 HIV-1 + 2 | 34 (2.3) | 54 (5.7) | 1 (0.1) | 14 (2.8) | 103 (2.6) |
 Missing | 12 (0.8) | 159 (16.7) | 26 (2.3) | 0 (0.0) | 197 (4.9) |
WHO stage | |||||
 Stage I | 586 (40.3) | 15 (1.6) | 323 (29.0) | 134 (26.8) | 1058 (26.3) |
 Stage II | 194 (13.4) | 24 (2.5) | 298 (26.8) | 106 (21.2) | 622 (15.5) |
 Stage III | 236 (16.2) | 31 (3.3) | 180 (16.2) | 179 (35.8) | 626 (15.6) |
 Stage IV | 30 (2.1) | 1 (0.1) | 87 (7.8) | 25 (5.0) | 143 (3.6) |
 Missing | 407 (28.0) | 880 (92.5) | 224 (20.1) | 56 (11.2) | 1567 (39.0) |
Abacavir based regimena | |||||
 No | 1277 (98.6) | 565 (87.9) | 1053 (98.2) | 498 (99.6) | 3393 (96.7) |
 Yes | 18 (1.4) | 78 (12.1) | 19 (1.8) | 2 (0.4) | 117 (3.3) |